{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=22&state=Florida", "query": { "state": "Florida", "city": "Jacksonville", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 7623, "total_pages": 763, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=23&state=Florida&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=21&state=Florida&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T02:53:02.772Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04458909", "title": "Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Nasopharyngeal Carcinoma", "Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Metastatic Nasopharyngeal Nonkeratinizing Carcinoma", "Metastatic Nasopharyngeal Undifferentiated Carcinoma", "Nasopharyngeal Nonkeratinizing Carcinoma", "Recurrent Nasopharyngeal Carcinoma", "Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma", "Recurrent Nasopharyngeal Undifferentiated Carcinoma", "Stage IV Nasopharyngeal Carcinoma AJCC v8", "Stage IVA Nasopharyngeal Carcinoma AJCC v8", "Stage IVB Nasopharyngeal Carcinoma AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2020-12-09", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-11-01T02:53:02.772Z", "location_count": 322, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 204 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04458909" }, { "nct_id": "NCT01798004", "title": "Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ganglioneuroblastoma", "Stage 1 Neuroblastoma", "Stage 2 Neuroblastoma", "Stage 2A Neuroblastoma", "Stage 2B Neuroblastoma", "Stage 3 Neuroblastoma", "Stage 4 Neuroblastoma", "Stage 4S Neuroblastoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 150, "start_date": "2013-04-09", "completion_date": "2024-06-30", "has_results": true, "last_update_posted_date": "2024-07-15", "last_synced_at": "2026-11-01T02:53:02.772Z", "location_count": 113, "location_summary": "Birmingham, Alabama • Downey, California • Duarte, California + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Downey", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01798004" }, { "nct_id": "NCT07089784", "title": "Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "MK-2828", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "24 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "24 Years to 75 Years" }, "enrollment_count": 46, "start_date": "2025-09-22", "completion_date": "2026-05-04", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-11-01T02:53:02.772Z", "location_count": 11, "location_summary": "Chula Vista, California • Glendale, California • Hallandale, Florida + 8 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Hallandale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07089784" }, { "nct_id": "NCT03309332", "title": "AMPLATZER PFO Occluder Post Approval Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stroke", "Patent Foramen Ovale" ], "interventions": [ { "name": "AMPLATZER™ PFO Occluder", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 1214, "start_date": "2018-01-31", "completion_date": "2030-02-05", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-11-01T02:53:02.772Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03309332" }, { "nct_id": "NCT06409130", "title": "Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol-related Liver Disease" ], "interventions": [ { "name": "NNC0194-0499", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "NNC0194-0499 placebo", "type": "DRUG" }, { "name": "Semaglutide placebo (Group A)", "type": "DRUG" }, { "name": "Cagrilintide + semaglutide", "type": "DRUG" }, { "name": "Cagrilintide", "type": "DRUG" }, { "name": "Cagrilintide placebo", "type": "DRUG" }, { "name": "Semaglutide placebo (Group B)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2024-05-20", "completion_date": "2026-01-12", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-11-01T02:53:02.772Z", "location_count": 29, "location_summary": "Chandler, Arizona • Tucson, Arizona • Lancaster, California + 23 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Lancaster", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06409130" }, { "nct_id": "NCT03541200", "title": "Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vasomotor Symptoms (VMS)" ], "interventions": [ { "name": "MT-8554", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tanabe Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 190, "start_date": "2018-04-18", "completion_date": "2019-11-15", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-11-01T02:53:02.772Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Norwalk", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03541200" }, { "nct_id": "NCT03631706", "title": "M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "M7824", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 304, "start_date": "2018-10-01", "completion_date": "2024-06-25", "has_results": true, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-11-01T02:53:02.772Z", "location_count": 25, "location_summary": "Huntsville, Alabama • Los Angeles, California • Orange, California + 21 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03631706" }, { "nct_id": "NCT03276728", "title": "Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Heart Failure", "Healthy Volunteer" ], "interventions": [ { "name": "AMG 986 IV", "type": "DRUG" }, { "name": "AMG 986 PO", "type": "DRUG" }, { "name": "Placebo PO", "type": "DRUG" }, { "name": "Placebo IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 182, "start_date": "2016-08-12", "completion_date": "2019-04-18", "has_results": true, "last_update_posted_date": "2022-08-08", "last_synced_at": "2026-11-01T02:53:02.772Z", "location_count": 8, "location_summary": "Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Tustin", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03276728" }, { "nct_id": "NCT00847067", "title": "Chronic Post Breast Surgery Pain", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Paravertebral block", "type": "PROCEDURE" }, { "name": "Sham injections", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 40, "start_date": "2009-02", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-11-01T02:53:02.772Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00847067" }, { "nct_id": "NCT03553836", "title": "Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 976, "start_date": "2018-09-12", "completion_date": "2033-10-12", "has_results": true, "last_update_posted_date": "2024-11-29", "last_synced_at": "2026-11-01T02:53:02.772Z", "location_count": 39, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03553836" } ] }